These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 29381974)
1. Stroke risks and patterns of warfarin therapy among atrial fibrillation patients post radiofrequency ablation: A real-world experience. Zhang J; Liu X; Liu X; Yin X; Wang Y; Lu X; Yang X Medicine (Baltimore); 2017 Nov; 96(47):e8762. PubMed ID: 29381974 [TBL] [Abstract][Full Text] [Related]
2. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744 [TBL] [Abstract][Full Text] [Related]
3. Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey. Marcucci M; Lip GY; Nieuwlaat R; Pisters R; Crijns HJ; Iorio A Am J Med; 2014 Oct; 127(10):979-986.e2. PubMed ID: 24838192 [TBL] [Abstract][Full Text] [Related]
4. The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation. Jacobs V; May HT; Bair TL; Crandall BG; Cutler M; Day JD; Weiss JP; Osborn JS; Muhlestein JB; Anderson JL; Mallender C; Bunch TJ Heart Rhythm; 2015 Apr; 12(4):681-6. PubMed ID: 25546809 [TBL] [Abstract][Full Text] [Related]
5. Comparison of HAS-BLED and HAS-BED Versus CHADS Poli D; Antonucci E; Pengo V; Testa S; Palareti G Am J Cardiol; 2017 Apr; 119(7):1012-1016. PubMed ID: 28237286 [TBL] [Abstract][Full Text] [Related]
6. Adherence to treatment guidelines: the association between stroke risk stratified comparing CHADS Chapman SA; St Hill CA; Little MM; Swanoski MT; Scheiner SR; Ware KB; Lutfiyya MN BMC Health Serv Res; 2017 Feb; 17(1):127. PubMed ID: 28187730 [TBL] [Abstract][Full Text] [Related]
7. Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry. Kornej J; Hindricks G; Kosiuk J; Arya A; Sommer P; Husser D; Rolf S; Richter S; Piorkowski C; Gaspar T; Lip GY; Bollmann A Circ Arrhythm Electrophysiol; 2013 Oct; 6(5):868-74. PubMed ID: 24047706 [TBL] [Abstract][Full Text] [Related]
8. How Well Do Stroke Risk Scores Predict Hemorrhage in Patients With Atrial Fibrillation? Quinn GR; Singer DE; Chang Y; Go AS; Borowsky LH; Fang MC Am J Cardiol; 2016 Sep; 118(5):697-9. PubMed ID: 27394408 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the CHA Yao X; Gersh BJ; Sangaralingham LR; Kent DM; Shah ND; Abraham NS; Noseworthy PA Am J Cardiol; 2017 Nov; 120(9):1549-1556. PubMed ID: 28844514 [TBL] [Abstract][Full Text] [Related]
10. Clinical update on the management of atrial fibrillation. Danelich IM; Reed BN; Hollis IB; Cook AM; Rodgers JE Pharmacotherapy; 2013 Apr; 33(4):422-46. PubMed ID: 23553811 [TBL] [Abstract][Full Text] [Related]
11. CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention. Puurunen MK; Kiviniemi T; Schlitt A; Rubboli A; Dietrich B; Karjalainen P; Nyman K; Niemelä M; Lip GY; Airaksinen KE Thromb Res; 2014 Apr; 133(4):560-6. PubMed ID: 24461143 [TBL] [Abstract][Full Text] [Related]
12. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial. Apostolakis S; Lane DA; Buller H; Lip GY Thromb Haemost; 2013 Nov; 110(5):1074-9. PubMed ID: 24048467 [TBL] [Abstract][Full Text] [Related]
13. The Effect of Bleeding Risk and Frailty Status on Anticoagulation Patterns in Octogenarians With Atrial Fibrillation: The FRAIL-AF Study. Lefebvre MC; St-Onge M; Glazer-Cavanagh M; Bell L; Kha Nguyen JN; Viet-Quoc Nguyen P; Tannenbaum C Can J Cardiol; 2016 Feb; 32(2):169-76. PubMed ID: 26277091 [TBL] [Abstract][Full Text] [Related]
14. Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study). Lip GYH; Merino JL; Dan GA; Themistoclakis S; Ellenbogen KA; De Caterina R; Goudev A; Jin J; Melino M; Winters SM; Goette A Am J Cardiol; 2018 Jan; 121(2):193-198. PubMed ID: 29169605 [TBL] [Abstract][Full Text] [Related]
15. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience. Barnes GD; Gu X; Haymart B; Kline-Rogers E; Almany S; Kozlowski J; Besley D; Krol GD; Froehlich JB; Kaatz S Thromb Res; 2014 Aug; 134(2):294-9. PubMed ID: 24929840 [TBL] [Abstract][Full Text] [Related]
16. Diagnostic Accuracy of the HAS-BLED Bleeding Score in VKA- or DOAC-Treated Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Gao X; Cai X; Yang Y; Zhou Y; Zhu W Front Cardiovasc Med; 2021; 8():757087. PubMed ID: 34881309 [No Abstract] [Full Text] [Related]
17. Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation. Guo Y; Wang H; Tian Y; Wang Y; Lip GYH Chest; 2015 Jul; 148(1):62-72. PubMed ID: 25501045 [TBL] [Abstract][Full Text] [Related]
18. Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA Rivera-Caravaca JM; Roldán V; Esteve-Pastor MA; Valdés M; Vicente V; Marín F; Lip GYH Am Heart J; 2018 Mar; 197():27-34. PubMed ID: 29447781 [TBL] [Abstract][Full Text] [Related]
19. Do physicians correctly calculate thromboembolic risk scores? A comparison of concordance between manual and computer-based calculation of CHADS2 and CHA2 DS2 -VASc scores. Esteve-Pastor MA; Marín F; Bertomeu-Martinez V; Roldán-Rabadán I; Cequier-Fillat Á; Badimon L; Muñiz-García J; Valdés M; Anguita-Sánchez M; Intern Med J; 2016 May; 46(5):583-9. PubMed ID: 26929032 [TBL] [Abstract][Full Text] [Related]
20. Net clinical benefit of edoxaban versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study. Blann AD; Banerjee A; Lane DA; Torp-Pedersen C; Lip GY Int J Cardiol; 2015 Dec; 201():693-8. PubMed ID: 26379097 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]